Urothelial Cancer Genomic Sequencing Study
Following the development of the first all-inclusive genomics test approved by the New York State Department of Health, the Englander Institute for Precision Medicine has made genetic sequencing widely available for cancer patients at NewYork-Presbyterian Hospital/Weill Cornell Medicine.
The objective of this research study is to assess the clinical importance of germline mutations in urothelial cancer (UC) by building a comprehensive registry of patients with the disease.
If you are a patient interested in precision medicine, please speak with your clinician or contact or submit inquiries and contact information to email@example.com
- NewYork-Presbyterian/Weill Cornell Medicine patients contact your clinician in the Department of Hematology and Medical Oncology to learn more
- NewYork-Presbyterian/Weill Cornell Medicine clinicians contact firstname.lastname@example.org for referrals
- Patients and clinicians at other institutions may submit inquiries and contact information to email@example.com
Weill Cornell Medicine’s Division of Hematology & Medical Oncology Clinic
Bishoy Morris Faltas, M.D.